| Drug Name |
Entacapone |
| Drug ID |
BADD_D00773 |
| Description |
Entacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor. |
| Indications and Usage |
Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off". |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N04BX02 |
| DrugBank ID |
DB00494
|
| KEGG ID |
D00781
|
| MeSH ID |
C071192
|
| PubChem ID |
5281081
|
| TTD Drug ID |
D0J1VY
|
| NDC Product Code |
64679-711; 65862-611; 49587-105; 33342-260; 27241-049; 47335-007; 46438-0005; 48087-0080; 43353-996; 50268-295; 0378-9080; 0527-1830; 0904-6822; 0078-0327; 52483-0201; 51079-273; 58032-2003; 0615-8298; 48087-0109; 52427-800; 65372-1149; 71610-247; 68022-7015; 0781-5578; 64679-781; 60687-188; 65085-0050; 68022-7043; 46708-478; 52483-0014; 62332-478; 65862-654; 68554-0068 |
| Synonyms |
entacapone | 2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide | Comtan | Comtess | OR 611 | OR-611 |
